Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA^® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.

Read more at globenewswire.com